IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib
Veronika Šandová(Central European Institute of Technology), Marek Mráz(Central European Institute of Technology), Jennifer R. Brown(Dana-Farber Cancer Institute), Michael Doubek(Central European Institute of Technology), Gabriela Mladonická Pavlasová(Central European Institute of Technology), Anna Panovská(Masaryk University), Jiřı́ Mayer(Masaryk University), Sonali Sharma(Central European Institute of Technology), Matthew S. Davids(Dana-Farber Cancer Institute), Yvona Brychtová(Masaryk University), Šárka Pospı́šilová(Central European Institute of Technology), Veronika Palušová(Masaryk University), Stacey M. Fernandes(Dana-Farber Cancer Institute), Kateřina Amruz Černá(Central European Institute of Technology), Václav Šeda(Central European Institute of Technology)
Cited by 22
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890